Ocuphire Pharma to Present at the Aegis Virtual Conference
Ocuphire Pharma, Inc. (OCUP)
Company Research
Source: GlobeNewswire
FARMINGTON HILLS, Mich., May 03, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of retinal and refractive eye disorders, today announced that George Magrath, M.D. M.B.A., M.S., Chief Executive Officer of Ocuphire, will present a company overview at the Aegis Virtual Conference being held May 7-9, 2024. Company management will also be participating in one-on-one meetings throughout the conference. Key details about Dr. Magrath’s presentation at the Aegis Capital Virtual Conference are below: Aegis Capital Virtual Conference – May 7-9, 2024 Title of Presentation:Ocuphire Pharma, Inc. (OCUP) Company PresentationPresenter:George Magrath, M.D. M.B.A, M.S.Date:Wednesday, May 8, 2024Time:3:00 – 3:25pm ET If you are interested in arranging a one-on-one meeting, please contact your conference representative or send an email to ir@ocuphire.com. For more details, please see th
Show less
Read more
Impact Snapshot
Event Time:
OCUP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCUP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCUP alerts
High impacting Ocuphire Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
OCUP
News
- Ocuphire Pharma, Inc. (NASDAQ: OCUP) was upgraded by analysts at Canaccord Genuity Group Inc. to a "strong-buy" rating.MarketBeat
- Ocuphire Pharma, Inc. (NASDAQ: OCUP) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $22.00 to $18.00. They now have a "buy" rating on the stock.MarketBeat
- Ocuphire Pharma, Inc. (NASDAQ: OCUP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.MarketBeat
- Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate UpdateGlobeNewswire
- Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual MeetingGlobeNewswire
OCUP
Earnings
- 11/13/23 - Beat
OCUP
Sec Filings
- 5/10/24 - Form 10-Q
- 5/10/24 - Form 8-K
- 5/10/24 - Form 8-K
- OCUP's page on the SEC website